Tell me about citalopram for depression

The short version: citalopram works modestly better than placebo for major depression, but the evidence is built on short-term trials, surrogate endpoints, and industry funding, and it carries a real cardiac risk that is often downplayed.

The largest network meta-analysis, covering 522 trials and over 116,000 people, found that all 21 antidepressants tested were more effective than placebo [6]. That sounds definitive. But 409 of those 522 trials were funded by pharmaceutical companies [6]. That is 78%. Industry-funded trials are more likely to produce positive results. The same analysis measured "acceptability" (dropout rate), not long-term safety. Most trials lasted 8 weeks [6]. Depression treatment often lasts years. The evidence for what happens after two months is thin.

The biggest safety signal is on your heart. Citalopram and its purified version escitalopram are among the antidepressants that require "greater caution" for QT interval prolongation [4]. That is a change in the heart's electrical cycle that can lead to a dangerous arrhythmia called torsades de pointes and sudden cardiac death [4]. A case report documented a 42-year-old woman whose QTc jumped from 452 ms to 503 ms after just two days on 5 mg of escitalopram, a low dose [5]. The prolongation reversed when she stopped the drug [5]. The FDA already caps citalopram at 40 mg per day (20 mg for people over 60) because of this risk. The mechanism is dose-dependent and well-established: the drug blocks the hERG potassium channel in heart muscle cells.

How well does it actually work? The STAR*D study, the largest real-world trial of citalopram, treated 2,876 outpatients. Only 27.5% achieved remission on the standard depression scale [1]. And of those who did, 90% still had residual symptoms, most commonly sleep disturbance and appetite changes [2]. The drug did not make most people well. It moved the needle modestly. A placebo-controlled trial comparing citalopram to sertraline found that citalopram reduced the HAMD depression score by about 14.5 points from a baseline of 26.5, while placebo dropped about 10 points [3]. That is a drug-placebo difference of roughly 4.5 points on a 52-point scale. Statistically significant. Clinically modest.

There is no long-term safety data in the evidence here. No study tracked all-cause mortality, cardiovascular events, or cancer incidence over years of use. The trials are short, the funding is conflicted, and the cardiac risk is real and dose-dependent. The burden of proof for a drug you may take for years has not been met by 8-week industry trials.

My call: citalopram offers a modest short-term benefit over placebo for major depression, but the evidence base is industry-funded, short-term, and does not rule out meaningful long-term harms, especially cardiac. Confidence: moderate for short-term efficacy, low for long-term safety.